Scott T. Aaronson, MD

Institute for Advanced Diagnostics and Therapeutics, Sheppard Pratt Health System, Baltimore, Maryland

Scott T. Aaronson, MD is affiliated with Institute for Advanced Diagnostics and Therapeutics, Sheppard Pratt Health System, Baltimore, Maryland. Scott T. Aaronson has authored or co-authored 10 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 2008 and 2026. Their work focuses on Depression (MDD), Suicide, Anxiety, Bipolar Disorder, and Posttraumatic Stress Disorder.

Depression (MDD) Suicide Anxiety Bipolar Disorder Posttraumatic Stress Disorder Psychedelics Psychotherapy

Frequent co-authors

Harold A. Sackeim A. John Rush Charles R. Conway David L. Dunner Brian J. Mickey Charles Gordon Christopher L. Kriedt John Zajecka
JCP
Impact of VNS on Suicidal Ideation in Markedly Treatment-Resistant Major Depression: A RECOVER Study Report
Original Research ▶ Video

July 8, 2026

Findings suggest that active VNS reduces suicidal ideation (SI) and potentially induces SI remission among participants with chronic TRD and baseline SI.
, , , et al
JCP
Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation
Original Research ▶ Video

May 13, 2026

A single psilocybin dose with psychological support was associated with rapid, large, and durable reductions in suicidal ideation and depressive symptoms.
, , , et al
JCP
Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report
Original Research

July 14, 2025

History of ECT use (lifetime and current episode) or TMS use (current episode) was prognostic of poorer outcomes across the total sample and superior benefit from active versus sham...
, , , et al
JCP
The Long Road Toward Equitable MDMA Treatment in the United States
Commentary

May 29, 2024

Kozak and Aaronson discuss challenges in implementation of MDMA-assisted therapy, including insurance and Medicare coverage as well as cultural barriers.
,
JCP
Pilot Study of High Frequency TMS for Bipolar Depression
Original Research

May 20, 2024

In this study of patients with bipolar depression, 87.1% reached response and 74.2% reached remission with 6 weeks of rTMS.
, , , et al
JCP
Long-Term Safety and Efficacy of Zuranolone in MDD
Original Research

December 27, 2023

Most patients with MDD achieved response after 14 days of zuranolone treatment. For patients who responded to their first treatment, the time to repeat treatment was over 4 months.
, , , et al
JCP
TMS in Anxious Depression
Original Research

January 11, 2023

Patients with anxious depression tend to have more severe depressive symptoms. This study examined the effects of transcranial magnetic stimulation in these patients.
, , , et al
JCP
Original Research

August 21, 2018

Vagus nerve stimulation (VNS) treatment has been shown to be efficacious in treatment-resistant depression (TRD). Can VNS treatment lead to improvements in quality of life in patients with TRD...
, , , et al
JCP
Original Research

September 16, 2014

, , , et al
JCP
Original Research

November 30, 2008

, , , et al

Live Webinar
and Q&A With
Dr Deligiannidis

JULY 16 · REGISTER NOW
Webinar ad featuring Dr. Kristina M. Deligiannidis on PPD treatment options

Subscribe to read
more articles

Subscribe